Lipoprotein modification by advanced glycosylation endproducts (AGEs): Role in atherosclerosis

Trends in Cardiovascular Medicine

Volumn 7, Issue 2, 1997, Pages 39-47

  Bucala, Richard ^a  

^a PICOWER INST FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; APOLIPOPROTEIN B; GLUCOSE; GLYCOSYLATED PROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE;

ATHEROSCLEROSIS; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPERTENSION; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW;

EID: 0030951770     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(96)00137-5     Document Type: Review

References (52)

1. Al-Abed Y, Liebich H, Voelter W, Bucala R: 1996. Hydroxyalkenal formation induced by LDL-advanced glycosylation of low density lipoprotein. J Biol Chem 271:2892-2896.
2. Barret-Conner E, Orchard T: 1985. Diabetes and heart disease. In Diabetes in America: Diabetes Data Compiled 1984. National Diabetes Data Group. NIH Pub No 85-1486.
3. Berliner JA, Territo MC, Sevanian A, et al. 1990. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions.J Clin Invest 85:1260-1266.
4. Brown WV: 1994. Lipoprotein disorders in diabetes mellitus. Med Clin N Amer 78:143-161.
5. Bucala R, Tracy KJ, Cerami A: 1991. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 87:432-438.
6. Bucala R, Cerami A: 1992. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 23:1-34.
7. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H: 1993. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 90:6434-6438.
8. Bucala R, Makita Z, Vega G, et al.: 1994. Modification of LDL by advanced glycosylation endproducts contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91:9441-9445.
9. Bucala R, Cerami A, Vlassara H: 1995a.Advanced glycosylation end products in diabetic complications: biochemical basis and prospects for therapeutic intervention. Diabetes Rev 3:258-268.
10. Bucala R, Mitchell R, Arnold K, Innerarity T, Vlassara H, Cerami A: 1995b. Identification of the major site of apolipoprotein-B modification by advanced glycosylation endproducts (AGEs) blocking uptake by the LDL receptor. J Biol Chem 270:10,828-10,832.
11. Bucala R: 1996. Lipid and lipoprotein oxidation: Basic mechanisms and unresolved questions in vivo. Redox Reports 2:291-307.
12. Chen GC, Hardman DA, Hamilton RL, et al.: 1989. Distribution of lipid-binding regions in human apolipoprotein B-100. Biochemistry 28:2477-2484.
13. Chen HJC, Cerami A: 1993. Mechanism of inhibition of advanced glycosylation by aminoguanidine in vitro. J Carbohydrate Chem 12:731-742.
14. De Tejada IS, Goldstein I, Azadzoi K, Krane RJ, Cohen RJR: 1989. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle in diabetic men with impotence. N Engl J Med 320:1025-1030.
15. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker LJ: 1992. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor.Proc Natl Acad Sci USA 89:2873-2877.
16. Esposito C, Gerlach H, Brett J, Stern D, Vlassara H: 1989. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties.J Exp Med 170:1387-1407.
17. Esterbauer H, Schaur RJ, Zollner H: 1991. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11:81-128.
18. Frei B, Stocker R, Ames BN: 1988. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA 85: 9748-9752.
19. Friedman EA: 1992.Treatment options for diabetic nephropathy. Diabetes Spectrum 5:6-16.
20. Garg UC, Hassid A: 1989. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83:1774-1777.
21. Halliwell BM, Gutteridge JMC: 1989. Free Radicals in Biology and Medicine. Oxford, Clarendon Press.
22. Hiramatsu K, Bierman EL, Chait A: 1985. Metabolism of low-density lipoprotein from patients with diabetic hypertriglyceridemia by cultured human skin fibroblasts. Diabetes 34: 8-14.
23. Hogan M, Cerami A, Bucala R: 1992. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. J Clin Invest 90:1110-1115.
24. Jensen T, Stender S, Deckert T: 1988. Abnormalities in plasma concentrations of lipoproteins and fibrinogen in type 1 diabetic patients with increased urinary albumin excretion. Diabetologia 31:142-145.
25. Klaasen CD, ed.: 1985.Heavy metals and heavy metal antagonists. In Gilman AG, Goodman LS, Rall TW, Murad F, eds. Goodman and Gilman's the Pharmacological Basis Of Therapeutics. New York, Macmillan, pp 1605-1627.
26. Lopes-Virella MF, Sherer GK, Lees AM, et al.: 1982. Surface binding, internalization, and degradation by cultured human fibroblasts of low density lipoproteins isolated from type 1 (insulin-dependent) diabetic patients: changes with metabolic control. Diabetologia 22:430-436.
27. Mahley RW, Innerarity TL, Pitas RE, Weisgraber KH, Brown JH, Gross E: 1977.Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apoproteins. J Biol Chem 252: 7279-7287.
28. Mahley RW, Innerarity TL, Weisgraber KH, Oh SY: 1979. Altered metabolism (in vivo and in vitro) of plasma lipoproteins after selective chemical modification. J Clin Invest 64:743-750.
29. Makita Z, Vlassara H, Rayfield E, et al.: 1992. Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 258:651-653.
30. Makita Z, Bucala R, Rayfield EJ, et al: 1994.Diabetic-uremic serum advanced glycosylation end products are chemically reactive and resistant to dialysis therapy. Lancet 343:1519-1522.
31. Mcveigh GE, Brennan GM, Johnston GD, et al.: 1992. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35:771-776.
32. Milne R, ThéOlis R, Maurice R, et al.: 1989. The use of monoclonal antibodies to localize the low density lipoprotein receptor-binding domain of apolipoprotein B. J Biol Chem 264: 19,754-19,760.
33. Nakamura Y, Horii Y, Nishino T, et al.: 1993. Immunohistochemical localization of advanced glycosylation endproducts (AGEs) in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 143:1649-1656.
34. Nishino T, Horii Y, Shiiki H, et al.: 1994. Immunohistochemical detection of advanced gly2cosylation end products (AGEs) within the vascular lesions and glomeruli in diabetic nephropathy. Human Path 26:308-313.
35. 2-(1-Carboxyethyl)guanine (CEG) as a guanine advanced glycosylation end product. Biochemistry 34:648-655.
36. Pyorala K, Laakso M, Vusitupra: 1987. Diabetes and atherosclerosis: an epidemiological view. Diabetes Metab Rev 3:464-524.
37. Rajavashisth TB, Andalibi A, Territo MC, et al.: 1990.Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 344:254-257.
38. Ross R: 1986.The pathogenesis of atherosclerosis. An update. N Engl J Med 314:488-500.
39. Schmidt AM, Vianna M, Gelach M, et al.: 1992. Isolation and characterization of two binding proteins for advanced glycosylation endproducts from bovine lung which are present on the endothelial cell surface. J Biol Chem 267: 14,987-14,997.
40. Shaw SM, Crabbe MJ: 1994 Non-specific binding of advanced-glycosylation end-products to macrophages outweighs specific receptor-mediated interactions. Biochem J 304:121-129.
41. Sowers JR, Levy J, Zemel MB: 1988. Hypertension and diabetes. Med Clin North Am 72: 1399-1414.
42. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: 1989. Modifications of low-density lipoprotein that increases its atherogenicity. Mech Dis 320:915-924.
43. Teuscher A, Egger M, Hermann JB: 1989. Diabetes and nephropathy: blood pressure in clinical diabetic patients and control population. Arch Intern Med 149:1942-1945.
44. United States Renal Data System. USRDS 1992 Annual Data Report. Bethesda, MD, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease.
45. Vasan S, Zhang X, Zhang X, et al.: 1996. An agent cleaving glucose-derived protein-crosslinks in vitro and in vivo. Nature 382: 275-278.
46. Vlassara H, Brownlee M, Cerami A: 1986. Novel macrophage receptor for glucose-modified protein is distinct from previously described scavenger receptors. J Exp Med 164:1301-1309.
47. Vlassara H, Brownlee M, Manogue K, Dinarello C, Cerami A: 1988. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 240:1546-1548.
48. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R: 1992. Exogenous advanced glycosylation endproducts induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci USA 89: 12,043-12,047.
49. Vlassara H, Li YM, Imani F, Wojciechowicz D, et al.: 1995a. Identification of galectin-3 as a high affinity binding protein for advanced glycation endproducts (AGE): a new member of the AGE-receptor complex. Mol Med1: 634-646.
50. Vlassara H, Fuh H, Donnelly T, Cybulsky M: 1995b. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1:447-456.
51. Wells-Knecht KJ, Lyons TJ, Mccance DR, Thorpe SR, Feather MS, Baynes JW: 1994. 3-Deoxyfructose concentrations are increased in human plasma and urine in diabetes. Diabetes 43:1152-1156.
52. Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elam R, Steinberg D: 1982. Nonenzymatic glycosylation of low-density lipoprotein alters its biologic activity. Diabetes 31: 283-291.